Complex genetic interactions affect susceptibility to Alzheimer's disease risk in the BIN1 and MS4A6A loci
- PMID: 39751715
- PMCID: PMC12181559
- DOI: 10.1007/s11357-024-01477-6
Complex genetic interactions affect susceptibility to Alzheimer's disease risk in the BIN1 and MS4A6A loci
Abstract
Genetics is the second strongest risk factor for Alzheimer's disease (AD) after age. More than 70 loci have been implicated in AD susceptibility so far, and the genetic architecture of AD entails both additive and nonadditive contributions from these loci. To better understand nonadditive impact of single-nucleotide polymorphisms (SNPs) on AD risk, we examined individual, joint, and interacting (SNPxSNP) effects of 139 and 66 SNPs mapped to the BIN1 and MS4A6A AD-associated loci, respectively. The analyses were conducted by fitting three respective dominant allelic-effect models using data from four independent studies. Joint effects were analyzed by considering pairwise combinations of genotypes of the selected SNPs, i.e., compound genotypes (CompG). The individual SNP analyses showed associations of 18 BIN1 SNPs and 4 MS4A6A SNPs with AD. We identified 589 BIN1 and 217 MS4A6A SNP pairs associated with AD in the CompG analysis, although their individual SNPs were not linked to AD independently. Notably, 34 BIN1 and 10 MS4A6A SNP pairs exhibited both significant SNPxSNP interaction effects and significant CompG effects. The vast majority of nonadditive effects were captured through the CompG analysis. These results expand the current understanding of the contributions of the BIN1 and MS4A6A loci to AD susceptibility. The identified nonadditive effects suggest a significant genetic modulation mechanism underlying the genetic heterogeneity of AD in these loci. Our findings highlight the importance of considering nonadditive genetic impacts on AD risk beyond the traditional SNPxSNP approximation, as they may uncover critical mechanisms not apparent when examining SNPs individually.
Keywords: Aging; Alzheimer’s disease; Compound genotypes; Dementia; Genetic associations; Genetic heterogeneity; Genetic interactions.
© 2025. The Author(s), under exclusive licence to American Aging Association.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study does not involve gathering data from human subjects directly. Instead, it focuses on secondary analysis of data obtained from dbGaP, NIAGADS, and the UK Biobank. The data were accessed with the approval of the Duke University Institutional Review Board (IRB) [protocols: Pro00105245-INIT-1.0 (06/26/2020), Pro00105247-INIT-1.0 (06/26/2020), and Pro00105346-INIT-1.0 (04/15/2020)], and all analyses were performed under IRB guidelines. Conflict of interest: The authors declare no conflicts of interest.
Figures


References
-
- Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement J Alzheimers Assoc. 2022;2022(18):700–89. - PubMed
-
- Marques SCF, Oliveira CR, Outeiro TF, Pereira CMF. Alzheimer’s disease: the quest to understand complexity. J Alzheimers Dis. 2010;21:373–83. - PubMed
-
- Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ. Epistasis in sporadic Alzheimer’s disease. Neurobiol Aging. 2009;30:1333–49. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical